Sökning: onr:"swepub:oai:gup.ub.gu.se/55706" >
Effect of spironola...
Effect of spironolactone on blood pressure in subjects with resistant hypertension
-
Chapman, N. (författare)
-
Dobson, J. (författare)
-
Wilson, S. (författare)
-
visa fler...
-
- Dahlöf, Björn, 1953 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för akut och kardiovaskulär medicin,Institute of Medicine, Department of Emergeny and Cardiovascular Medicine
-
Sever, P. S. (författare)
-
Wedel, H. (författare)
-
Poulter, N. R. (författare)
-
visa färre...
-
(creator_code:org_t)
- 2007
- 2007
- Engelska.
-
Ingår i: Hypertension. - 1524-4563. ; 49:4, s. 839-45
- Relaterad länk:
-
https://gup.ub.gu.se...
Abstract
Ämnesord
Stäng
- Spironolactone is recommended as fourth-line therapy for essential hypertension despite few supporting data for this indication. We evaluated the effect among 1411 participants in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm who received spironolactone mainly as a fourth-line antihypertensive agent for uncontrolled blood pressure and who had valid BP measurements before and during spironolactone treatment. Among those who received spironolactone, the mean age was 63 years (SD: +/-8 years), 77% were men, and 40% had diabetes. Spironolactone was initiated a median of 3.2 years (interquartile range: 2.0 to 4.4 years) after randomization and added to a mean of 2.9 (SD: +/-0.9) other antihypertensive drugs. The median duration of spironolactone treatment was 1.3 years (interquartile range: 0.6 to 2.6 years). The median dose of spironolactone was 25 mg (interquartile range: 25 to 50 mg) at both the start and end of the observation period. During spironolactone therapy, mean blood pressure fell from 156.9/85.3 mm Hg (SD: +/-18.0/11.5 mm Hg) by 21.9/9.5 mm Hg (95% CI: 20.8 to 23.0/9.0 to 10.1 mm Hg; P<0.001); the BP reduction was largely unaffected by age, sex, smoking, and diabetic status. Spironolactone was generally well tolerated; 6% of participants discontinued the drug because of adverse effects. The most frequent adverse events were gynecomastia or breast discomfort and biochemical abnormalities (principally hyperkaliemia), which were recorded as adverse events in 6% and 2% of participants, respectively. In conclusion, spironolactone effectively lowers blood pressure in patients with hypertension uncontrolled by a mean of approximately 3 other drugs. Although nonrandomized and not placebo controlled, these data support the use of spironolactone in uncontrolled hypertension.
Nyckelord
- Aged
- Aldosterone Antagonists/adverse effects/*therapeutic use
- Antihypertensive Agents/therapeutic use
- Blood Pressure/*drug effects
- Breast/drug effects
- Drug Resistance
- Female
- Gynecomastia/chemically induced
- Humans
- Hyperkalemia/chemically induced
- Hypertension/*drug therapy
- Male
- Middle Aged
- Pain/chemically induced
- Retreatment
- Spironolactone/adverse effects/*therapeutic use
- Treatment Outcome
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas